25th September 2020

(1) BSE Ltd
   Listing Department
   Phiroze Jeejeebhoy Towers,
   Dalal Street,
   Mumbai - 400 001

   Scrip Code: 500087

(2) National Stock Exchange of India Ltd
   Listing Department
   Exchange Plaza, 5th floor,
   Plot no. C/1, G Block,
   Bandra Kurla Complex,
   Bandra (East), Mumbai - 400 051

   Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
   Societe Anonyme
   35A Boulevard Joseph II,
   L-1840 Luxembourg

Sub: Press Release – Cipla receives final approval for generic version of Biogen IDEC Inc.’s Tecfidera® (Dimethyl Fumarate DR Capsules 120mg, 240mg and 120mg/240mg Starter Pack)

Dear Sir / Madam,

Please find enclosed press release dated 25th September 2020 for the captioned subject.

This is for your information and records.

Kindly acknowledge the receipt.

Thanking you,

Yours faithfully,
For Cipla Limited

RAJENDRA CHOPRA
Rajendra Chopra
Company Secretary

Encl.as above

Prepared by: Juzer Masta
Press Release

Cipla receives final approval for generic version of Biogen IDEC Inc.’s Tecfidera® (Dimethyl Fumarate DR Capsules 120mg, 240mg and 120mg/240mg Starter Pack)

Mumbai, India; September 25, 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Dimethyl Fumarate DR Capsules 120mg, 240mg and 120mg/240mg Starter Pak from the United States Food and Drug Administration (US FDA).

Cipla’s Dimethyl Fumarate DR Caps 120mg, 240mg and 120mg/240mg Starter Pak is AB-rated generic therapeutic equivalent version of Biogen IDEC Inc.’s Tecfidera®. It is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

According to IQVIA (IMS Health), Tecfidera® had US sales of approximately $3.8 Billion for the 12-month period ending July 2020.

The product is available for shipping immediately. Cipla will providing Co-Pay Assistance.

About Cipla:

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS
segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT July’20), 3rd largest in the pharma private market in South Africa (IQVIA MAT July’20), and is among the most dispensed generic players in the U.S. For over eight decades, making a difference to patients has inspired every aspect of Cipla’s work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla’s humanitarian approach to healthcare in pursuit of its purpose of ‘Caring for Life’ and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit www.cipla.com, or click on Twitter, Facebook, LinkedIn.

For queries, please contact:

Cipla Corporate Communications
Heena Kanal
E-Mail: CorpComm@cipla.com

Cipla Investor Relations
Naveen Bansal
E-Mail: Investor.Relations@cipla.com